Lightnews — Scholar-powered news

Jia (Jenny) Liu MD PhD

@jiajennyliu.bsky.social

2.2K followers 1.2K following 77 posts

Early Phase Trials Medical Oncologist / Translational Researcher 👩🏻‍⚕️ @kinghorncancer St Vincent’s Hospital Sydney @CMRI Senior Lecturer @UNSW. MOGA Exec. #PrecisionMedicine #drugdevelopment Passionate about mentorship ❤️ / wellness 🤸🏻‍♀️/ communication 🧬📣

Posts Media Videos Starter Packs

Pinned

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Jan 15

Oncology drug development 🧬💊 has come a long way, but the system is riddled with inefficiency, inequity and costs are ⏫.

Excited to share our 🌎 review article in press in JCO
@ascocancer.bsky.social
highlighting role of early phase consortia in tackling these challenges: 🧵 1)

#medsky #oncsky

1 6

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · 27d

EOI for the @MOGA_ORG Mentorship Program #NOMP25 closing soon!

We invite all 🇦🇺 med onc consultants and trainees to sign up. Benefits include networking outside your workplace, support to address career navigation, wellbeing and burnout.

🔗: shorturl.at/pS3Fg

1 1

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

ascopubs.org/doi/10.1200/...

Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors

PURPOSEThis early-phase study evaluated safety/tolerability, pharmacokinetics, and preliminary efficacy of dendrimer-nanoparticle delivery platform (DEP)-SN38, a polylysine-based nanoparticle conjugat...

ascopubs.org

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅‍♀️ No cholinergic symptoms observed

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Aug 6

Our early-phase trial of DEP-SN38, a poly-lysine dendrimer–conjugated SN38 platform, is now published @ascocancer.bsky.social #JCO @oncocook.bsky.social
💡As TOP1I ADC programs rise, there's growing interest in better payload delivery—and not just through antibodies.
Can dendrimers assist? ⬇️🧵

1 2

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Jul 11

One week until the inaugural #ESMOTATAsia25 🤩
I'm looking forward to joining global drug development experts in🍜🇭🇰
+ sharing insights on dose optimisation of novel combinations
🗓️ Saturday 19 July 2pm.
@myesmo.bsky.social @herbloongmd.bsky.social @anmwongnz.bsky.social

2 7

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Jun 17

Live Webinar @cmri_aus
Unlocking Proteomics for Smarter ADC Development
🗓 Thurs 26 June 2025 | 4–5:15 PM AEST

Join us on mass spec-based proteomics to accelerate and refine ADC development.

events.teams.microsoft.com/event/271eed...

Microsoft Virtual Events Powered by Teams

events.teams.microsoft.com

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Jun 16

Come work with us St Vincent's Private Hospital Sydney! 🏥🧬🩺

Position for oncology / hematology career medical officer now open:

svha.wd3.myworkdayjobs.com/en-GB/SVHA_S...

Oncology/Haematology CMO

Job Description: Better and fairer care. Always. We are St Vincent’s Health Australia, Australia’s largest not-for-profit provider of health and aged care services. Founded by The Sisters of Charity i...

svha.wd3.myworkdayjobs.com

Reposted by Jia (Jenny) Liu MD PhD

JAMA @jama.com · May 15

Atezolizumab did not improve clinical outcomes in patients with locally advanced squamous cell carcinoma of the head and neck at high risk of disease progression after multimodal definitive treatment.

https://ja.ma/4jVjthY

Visual Abstract. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

1 2

Reposted by Jia (Jenny) Liu MD PhD

OncoDaily @oncodaily.bsky.social · May 1

AACR12 vs AACR25 - Jia Liu

@jiajennyliu.bsky.social @theaacr.bsky.social @kinghorncancer.bsky.social

oncodaily.com/blog/jia-liu...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AACR25 #AACR12

Jia Liu: AACR12 vs AACR25 - OncoDaily

Jia Liu: AACR12 vs AACR25 / AACR12, AACR2025, AACR25, cancer, Jia Liu, OncoDaily, Oncology, Patricia LoRusso

oncodaily.com

1 8

Reposted by Jia (Jenny) Liu MD PhD

Yale Cancer Center @yalecancer.bsky.social · Apr 28

Drs. Michael Cecchini and @jiajennyliu.bsky.social co-chair an exciting symposium #AACR25 on new antibody drug conjugate (ADC) and immuno-oncology focused approaches to treating #cancer.
@theaacr.bsky.social

1 2

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 27

A powerful conclusion to the opening ceremony of #AACR25 - cancer research saves lives 💚 @theaacr.bsky.social

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 26

Incredible #AACR25 #WICR leadership workshop on now on building resilience in science 🔬🧬💃
loving the networking and open discussions + 🥗🥪🍪
@theaacr.bsky.social @hfpconsulting.bsky.social

1 3

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 25

Link to preprint for further details ➡️ arxiv.org/abs/2409.15663

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 25

Great workshop and talk #YingYuan
@mdanderson.bsky.social @fda.gov
on 🔧 backfill strategies in early phase trials including novel BARD covariate-adaptive randomisation strategies allowing dose escalation, backfill and randomisation data to ⏫ efficiency of 🧬 trials #ProjectOptimus #AACR25

1 1

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 24

Yes it’s amazing app, helpful if you have multiple long haul flights which is frequently my problem working in drug development from 🇦🇺! You get a trial and if you like it worth buying the annual subscription

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 23

It’s that time of the year again… Getting ready to 🦹‍♀️timeshift - heading to @AACR #AACR25 and looking forward to connecting with 🌍 colleagues very soon!

1 3

Reposted by Jia (Jenny) Liu MD PhD

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Apr 21

Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social

Trodelvy Plus Keytruda Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD L1 Metastatic Triple Negativ...

www.gilead.com

4 9

Reposted by Jia (Jenny) Liu MD PhD

Emil Lou, MD,PhD,FACP @cancerassassin1.bsky.social · Apr 21

Looking forward to the @theaacr.bsky.social Annual Meeting taking place in #Chicago beginning later this week for the latest/greatest in #cancerresearch. Follow the #AACR25 tag and the Social Media Ambassador team for insights throughout the Meeting.

2 4 27

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 14

Browse #AACR25 program: ➡️ www.aacr.org/meeting/aacr...

If you are at #AACR25 👋 come say hi at the ADCs and Immunooncology-focused Biological Approaches mini orals 27th April 3-5pm, where I look forward to co-chairing with my esteemed colleague from Yale A/Prof #MichaelCecchini

Program

Explore the scientific program for the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.

www.aacr.org

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 14

⭐ Immunotherapy trials dominate the Phase III trials
⭐ Progress in KRAS targeted therapies, PARP and novel approaches to deploy immunotherapy and WRN inhibitors in neoadj/adj settings
⭐ NSCLC has own plenary track!
⭐ Cellular therapy - CART/NK/TIL exciting advances in P1

1 1

Jia (Jenny) Liu MD PhD @jiajennyliu.bsky.social · Apr 14

@theaacr.bsky.social #AACR25 meeting less than 2 wks away! I’m looking forward to the clinical trials sessions in this years' meeting 'Unifying Cancer Science and Medicine: a continuum for innovation for impact' 🤝 #PatriciaLorusso

Overview of 37 oral abstracts ⬇️

1 4

Reposted by Jia (Jenny) Liu MD PhD

Ben Smith @bensmithphd.bsky.social · Apr 3

🚨New 2 min🎞️summarising step-by-step plan to address fear of #cancer recurrence in clinical practice.
Watch youtu.be/cr_3KEOTAv8?...
Read the 📰 👉 link.springer.com/article/10.1...
Listen to the podcast w/ @bogda-koczwara.bsky.social & Sophie Lebel🎙️ oncologynews.com.au/clinical-foc...
Explanatory🧵👇

Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence

YouTube video by The Daffodil Centre

youtu.be

1 6 9